HC Wainwright Issues Optimistic Estimate for MBRX Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at HC Wainwright lifted their Q3 2026 earnings estimates for Moleculin Biotech in a research report issued on Friday, August 28th. HC Wainwright analyst S. Nik now expects that the company will post earnings of ($0.45) per share for the quarter, up from their prior estimate of ($1.07). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($3.01) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.27) EPS and FY2027 earnings at ($0.70) EPS.

A number of other research analysts have also issued reports on MBRX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $3.00.

Moleculin Biotech Trading Down 0.8%

Shares of MBRX opened at $0.64 on Tuesday. The firm has a market cap of $12.56 million, a P/E ratio of -0.09 and a beta of 1.84. Moleculin Biotech has a 12 month low of $0.16 and a 12 month high of $15.75. The stock’s 50 day moving average is $1.57 and its two-hundred day moving average is $2.20.

Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Thursday, August 13th. The company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.15.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC purchased a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.